» Authors » Viet T Le

Viet T Le

Explore the profile of Viet T Le including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 443
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Horne B, Anderson J, May H, Bair T, Le V, Iverson L, et al.
Front Endocrinol (Lausanne) . 2025 Feb; 15:1401780. PMID: 39991046
Introduction: Water-only fasting for one day or more may provide health benefits independent of weight loss. Human growth hormone (HGH) may play a key role in multiple fasting-triggered mechanisms. Whether...
2.
Perpetua E, Palmer R, Le V, Al-Khatib S, Beavers C, Beckman J, et al.
JACC Adv . 2024 Aug; 3(7):100981. PMID: 39130036
Shared decision-making (SDM) and multidisciplinary team-based care delivery are recommended across several cardiology clinical practice guidelines. However, evidence for benefit and guidance on implementation are limited. Informed consent, the use...
3.
Horne B, Anderson J, Haddad F, May H, Le V, Knight S, et al.
Nutrients . 2024 Jul; 16(13). PMID: 38999823
Background: Periodic fasting was previously associated with greater longevity and a lower incidence of heart failure (HF) in a pre-pandemic population. In patients with coronavirus disease 2019 (COVID-19), periodic fasting...
4.
Anderson J, Knowlton K, May H, Le V, Lappe D, Cripps S, et al.
JACC Adv . 2024 Jun; 2(10):100676. PMID: 38938499
Background: Statins can improve outcomes in high-risk primary prevention populations. However, application in clinical practice has lagged. Objectives: The objective of this study was to compare an active vs a...
5.
Anderson J, May H, Le V, Muhlestein J, Horne B, Bair T, et al.
JACC Adv . 2024 Jun; 2(4):100385. PMID: 38938227
Background: The use of statins in patients with heart failure (HF) is controversial. In patients without HF, statins reduce atherosclerotic cardiovascular disease (ASCVD) risk, including HF-related events. However, in some...
6.
Anderson J, Knight S, Dong L, May H, Le V, Bair T, et al.
J Clin Med . 2024 May; 13(9). PMID: 38731098
: Recent reports have highlighted myocardial infarction (MI) patients without standard modifiable risk factors (SMRF), noting them to be surprisingly common and to have a substantial risk of adverse outcomes....
7.
Horne B, Anderson J, May H, Le V, Bair T, Bennett S, et al.
Int J Cardiol Cardiovasc Risk Prev . 2023 Sep; 19:200209. PMID: 37727698
Background: Intermittent fasting may increase longevity and lower cardiometabolic risk. This study evaluated whether fasting modifies clinical risk scores for mortality [i.e., Intermountain Mortality Risk Score (IMRS)] or chronic diseases...
8.
Le V, Knight S, Watrous J, Najhawan M, Dao K, McCubrey R, et al.
Front Cardiovasc Med . 2023 Sep; 10:1229130. PMID: 37680562
Introduction: Long-chain omega-3 polyunsaturated fatty acids (OM3 PUFA) are commonly used for cardiovascular disease prevention. High-dose eicosapentaenoic acid (EPA) is reported to reduce major adverse cardiovascular events (MACE); however, a...
9.
Buckler A, Doros G, Kinninger A, Lakshmanan S, Le V, Libby P, et al.
Front Cardiovasc Med . 2023 Aug; 10:1204071. PMID: 37600044
Aims: Residual cardiovascular risk persists despite statin therapy. In REDUCE-IT, icosapent ethyl (IPE) reduced total events, but the mechanisms of benefit are not fully understood. EVAPORATE evaluated the effects of...
10.
Anderson J, Knight S, May H, Le V, Bair T, Knowlton K, et al.
J Clin Med . 2023 May; 12(9). PMID: 37176703
Patients with ST-elevation myocardial infarction (STEMI), but without standard modifiable risk factors (SMuRF-less), are surprisingly common and appear to have a worse, or at best similar, short-term prognosis. However, relatively...